Abstract
Background and Aim
The clinical impact and complications of hepatogenous diabetes (HD) on cirrhosis have not been elucidated. This study aimed to evaluate the relationship of HD with portal hypertension (PHT) and variceal hemorrhage and to assess the prevalence of HD.
Methods
From July 2007 to December 2009, 75-g oral glucose tolerance test and insulin resistance (IR) were evaluated for 195 consecutive cirrhotic liver patients (M:F = 164:1, 53.0 ± 10.2 years) who had no history of diabetes mellitus. IR was calculated using the homeostasis model of assessment-insulin resistance (HOMA-IR) formula. Endoscopy for varices, hepatic venous pressure gradient (HVPG), and serologic tests were also conducted.
Results
HD was observed in 55.4 % (108/194) of the patients. Among them, 62.0 % required OGTT for diagnosis because they did not show an abnormal fasting plasma glucose level. The presence of HD showed a significant correlation with high Child–Pugh’s score, variceal hemorrhage, and HVPG (p = 0.004, 0.002, and 0.019, respectively). In multivariate analysis, Child–Pugh’s score (OR 1.43, 95 % CI 1.005–2.038) and HVPG (OR 1.15, 95 % CI 1.003–2.547) had significant relationships with HD. Patients with recent variceal hemorrhages (within 6 months) exhibited significantly higher glucose levels at 120 min in OGTT compared to patients without hemorrhages (p = 0.042). However, there was no difference in fasting glucose levels. The 120-min glucose level and HOMA-IR score were significantly and linearly correlated with HVPG (r 2 = 0.189, p < 0.001 and r 2 = 0.033, p = 0.011, respectively).
Conclusion
HD and IR have significant relationships with PHT and variceal hemorrhage. Postprandial hyperglycemia in particular had a significant relationship with variceal hemorrhage.
Similar content being viewed by others
Abbreviations
- HD:
-
Hepatogenous diabetes
- HVPG:
-
Hepatic venous pressure gradient
- MELD:
-
Model for end-stage liver disease
References
Del Vecchio Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract. 1990;8:29–36.
Buzzelli G, Chiarantini E, Cotrozzi G, et al. Estimate of prevalence of glucose intolerance in chronic liver disease. Degree of agreement among some diagnostic criteria. Liver. 1988;8:354–359.
Megyesi C, Samols E, Marks V. Glucose tolerance and diabetes in chronic liver disease. Lancet. 1967;2:1051–1056.
Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol. 2002;17:677–681.
Nishida T, Tsuji S, Tsujii M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol. 2006;101:70–75.
Bianchi G, Marchesini G, Zoli M, et al. Prognostic significance of diabetes in patients with cirrhosis. Hepatology. 1994;20:119–125.
Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22:24–27.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46:922–938.
Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39:280–282.
Lebrec D. Methods to evaluate portal hypertension. Gastroenterol Clin N Am. 1992;21:41–59.
Kim MY, Baik SK, Yea CJ, et al. Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis. Eur J Gastroenterol Hepatol. 2009;21:1241–1246.
Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep. 2003;3:279–288.
Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007;46:927–934.
Svegliati-Baroni G, Ridolfi F, Di Sario A, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology. 1999;29:1743–1751.
Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–744.
Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis. 2006;10:459–479, vii–viii.
Suk KT, Baik SK, Yoon JH, et al. Revision and update on clinical practice guideline for liver cirrhosis. Clin Mol Hepatol. 2012;18:1–21.
Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab. 2006;2:335–348.
Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010;16:347–352.
Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–809.
Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol. 2005;42:S85–S92.
Pardy BJ, Spencer RC, Dudley HA. Hepatic reticuloendothelial protection against bacteremia in experimental hemorrhagic shock. Surgery. 1977;81:193–197.
Pugliese D, Lee SS, Koshy A, et al. Systemic and splanchnic hemodynamic effects of intravenous hypertonic glucose in patients with cirrhosis. Hepatology. 1988;8:643–646.
Moreau R, Chagneau C, Heller J, et al. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. Scand J Gastroenterol. 2001;36:303–308.
Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rat: studies in basal conditions and on exposure to hemorrhagic shock. Gastroenterology. 1993;104:1722–1726.
Kruszynska YT, Harry DS, Bergman RN, McIntyre N. Insulin sensitivity, insulin secretion and glucose effectiveness in diabetic and non-diabetic cirrhotic patients. Diabetologia. 1993;36:121–128.
Cavallo-Perin P, Cassader M, Bozzo C, et al. Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect. J Clin Invest. 1985;75:1659–1665.
Petrides AS. Hepatogenic diabetes: pathophysiology, therapeutic options and prognosis. Zeitschrift fur Gastroenterologie. 1999;15–21.
Muller MJ, Willmann O, Rieger A, et al. Mechanism of insulin resistance associated with liver cirrhosis. Gastroenterology. 1992;102:2033–2041.
Camma C, Petta S, Di Marco V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology. 2009;49:195–203.
Gentile S, Turco S, Guarino G, et al. Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab. 2001;3:33–40.
Acknowledgment
This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020 and A100054).
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
Hyo Keun Jeon and Moon Young Kim have contributed equally to this research.
Rights and permissions
About this article
Cite this article
Jeon, H.K., Kim, M.Y., Baik, S.K. et al. Hepatogenous Diabetes in Cirrhosis Is Related to Portal Pressure and Variceal Hemorrhage. Dig Dis Sci 58, 3335–3341 (2013). https://doi.org/10.1007/s10620-013-2802-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2802-y